Related content

Recombinant Human Factor X - A two-component therapeutic for the treatment of coagulopathies particularly hemophilia with inhibitor

By Himmelspach M.   Pfleiderer M.   Fischer B.E.   Plaimauer B.   Antoine G.   Falkner F.G.   Dorner F.   Schlokat U.  

Thrombosis Research, Vol. 97, Iss. 2, 2000-01 ,pp. : 51-67

Elsevier

Access to resources Recommend Favorite

Immunological Characterization of Factor VIII Autoantibodies in Patients with Acquired Hemophilia A in the Presence or Absence of Underlying Disease

By Matsumoto T.   Shima M.   Fukuda K.   Nogami K.   Giddings J.C.   Murakami T.   Tanaka I.   Yoshioka A.  

Thrombosis Research, Vol. 104, Iss. 6, 2001-12 ,pp. : 381-388

Elsevier

Access to resources Recommend Favorite

In Hemophilia A and Autoantibody Inhibitor Patients: The Factor VIII A2 Domain and Light Chain Are Most Immunogenic

By Scandella D.H.   Nakai H.   Felch M.   Mondorf W.   Scharrer I.   Hoyer L.W.   Saenko E.L.  

Thrombosis Research, Vol. 101, Iss. 5, 2001-03 ,pp. : 377-385

Elsevier

Access to resources Recommend Favorite

Retention of tocilizumab and anti-tumour necrosis factor drugs in the treatment of rheumatoid arthritis

By Hishitani Y   Ogata A   Shima Y   Hirano T   Ebina K   Kunugiza Y   Shi K   Narazaki M   Hagihara K   Tomita T   Yoshikawa H   Tanaka T   Kumanogoh A  

Scandinavian Journal of Rheumatology, Vol. 42, Iss. 4, 2013-08 ,pp. : 253-259

Informa Healthcare

Access to resources Recommend Favorite

Co-present rheumatoid arthritis and gout successfully treated with abatacept

By Puszczewicz Mariusz   Ociepa-Zawal Marta  

Clinical Rheumatology, Vol. 28, Iss. 1, 2009-01 ,pp. : 105-105

Springer Publishing Company

Access to resources Recommend Favorite